Z. Novák, Michael A Gold, Jørn Herrstedt, S. Gill, Antonella Savarese, John Diaz, Stefan Kommoss, Guilherme Cantuaria, I. Boere, E. Fleming, L. Gilbert, K. Pennington, R. Holloway, E. Miller, Rachel Miller, M. Powell, Christine Dabrowski, S. Stevens, M. Mirza, C. Mccourt
{"title":"639 原发性晚期或复发性子宫内膜癌患者免疫相关不良事件的管理:ENGOT-EN6-NSGO/GOG-3031/RUBY试验中多司他(dostarlimab)联合化疗与单纯化疗的比较","authors":"Z. Novák, Michael A Gold, Jørn Herrstedt, S. Gill, Antonella Savarese, John Diaz, Stefan Kommoss, Guilherme Cantuaria, I. Boere, E. Fleming, L. Gilbert, K. Pennington, R. Holloway, E. Miller, Rachel Miller, M. Powell, Christine Dabrowski, S. Stevens, M. Mirza, C. Mccourt","doi":"10.1136/ijgc-2024-esgo.34","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":517822,"journal":{"name":"Oral Sessions","volume":"27 6","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"639 Management of immune-related adverse events in patients with primary advanced or recurrent endometrial cancer: dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial\",\"authors\":\"Z. Novák, Michael A Gold, Jørn Herrstedt, S. Gill, Antonella Savarese, John Diaz, Stefan Kommoss, Guilherme Cantuaria, I. Boere, E. Fleming, L. Gilbert, K. Pennington, R. Holloway, E. Miller, Rachel Miller, M. Powell, Christine Dabrowski, S. Stevens, M. Mirza, C. Mccourt\",\"doi\":\"10.1136/ijgc-2024-esgo.34\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":517822,\"journal\":{\"name\":\"Oral Sessions\",\"volume\":\"27 6\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oral Sessions\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ijgc-2024-esgo.34\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral Sessions","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2024-esgo.34","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
639 Management of immune-related adverse events in patients with primary advanced or recurrent endometrial cancer: dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial